The Russian Direct Investment Fund (RDIF) received an order for 100 million doses of Sputnik V coronavirus vaccine from a pharmaceutical company in India, a source familiar with the situation told RIA Novosti. Details are not provided.
In August, Russia was the first in the world to register a COVID-19 vaccine developed at the Gamaleya Center in cooperation with RDIF.
During the tests, the drug formed a stable humoral and cellular immune response in one hundred percent of the study participants and did not cause serious adverse events in them according to any of the criteria. At the same time, the level of neutralizing antibodies in vaccinated volunteers was 1.4-1.5 times higher than the level of antibodies in people who had been ill.
Last week, the first batch was released into civilian circulation, at the same time the third phase of clinical trials began, for which more than 30 thousand volunteers were recruited. Also Belarus is participating in the tests.
Mass vaccination of Russians will begin as production increases and information accumulates from post-registration studies, the Ministry of Health said.